Should Gynecomastia on Testosterone Be Surgically Removed?

Viewing This Video Is A Member Exclusive Feature

But you don’t need membership to get Dr. O’Connor’s insight on this topic, it’s in the summary, key takeaways, and related drugs and conditions below.

Want to watch the full video? Join the Health Portal Today.

Join Now

Already a member? Sign In

Timeline

00:00

Dr. O’Connor addresses a man who developed a one-sided breast mass after eight years on testosterone and is considering gynecomastia surgery. He explains why a new breast mass should first be properly evaluated and differentiated from other causes before deciding how to treat it.

02:20

Dr. O’Connor shifts to distinguishing true gynecomastia from excess chest fat and discusses when specialist surgery may be appropriate. He recommends seeking a plastic surgeon with significant gynecomastia experience rather than assuming any general surgeon will produce the same result.

04:30

Dr. O’Connor explains why he does not recommend chronic aromatase inhibitors, tamoxifen, or raloxifene to shrink an established gynecomastia mass. He describes mature gynecomastia as hardened fibrotic glandular tissue and discusses the potential consequences of aggressively suppressing estrogen.

06:05

Dr. O’Connor emphasizes a broader medical principle of excluding serious diagnoses before assuming a symptom is benign. For a breast mass in a man using testosterone or anabolic steroids, he stresses determining what the mass actually is before choosing treatment.

Video Summary

A new breast mass on testosterone deserves careful evaluation before assuming it is simply gynecomastia. Dr. O’Connor responds to a man who has used approximately 100 mg of testosterone weekly for eight years and developed a mass on the left side of his chest. He emphasizes that any new male breast mass should first be properly evaluated rather than automatically attributed to testosterone or estrogen.

Dr. O’Connor distinguishes between breast tenderness or burning sensations and a true physical gynecomastia mass. He also discusses the difference between excess chest fat and established glandular tissue, noting that becoming leaner may reveal rather than eliminate an existing gynecomastia mass.

Once a true hardened or fibrotic gynecomastia mass is established, Dr. O’Connor recommends consulting a plastic surgeon who has significant experience performing gynecomastia procedures. He stresses that specialization matters because cosmetic appearance and complete management of the tissue require experience with this specific operation.

Dr. O’Connor strongly disagrees with keeping men on aromatase inhibitors, tamoxifen, or raloxifene in an attempt to shrink an established fibrotic mass. He explains that aggressively suppressing estrogen can affect the central nervous system, cardiovascular system, joints, and overall health while failing to eliminate hardened gynecomastia tissue.

The larger clinical message is to determine what a breast mass actually represents before treating it. Dr. O’Connor emphasizes excluding serious causes such as breast cancer first, distinguishing true gynecomastia from body fat or other breast changes, and then selecting treatment based on the actual diagnosis rather than automatically adding estrogen-blocking medications.

Drug Callouts

Testosterone

Testosterone is the androgen used by the man who developed a unilateral breast mass after approximately eight years of treatment. The discussion focuses on correctly evaluating gynecomastia and breast changes in men using testosterone rather than automatically treating them by suppressing estrogen.

Aromatase Inhibitors

Aromatase inhibitors reduce the conversion of testosterone into estradiol. Dr. O’Connor strongly cautions against chronically suppressing estrogen with these drugs in an attempt to eliminate an established fibrotic gynecomastia mass.

Tamoxifen

Tamoxifen is a selective estrogen receptor modulator that affects estrogen signaling. It is discussed as a medication sometimes used in attempts to manage gynecomastia, but Dr. O’Connor argues against relying on it to shrink an established hardened mass.

Raloxifene

Raloxifene is a selective estrogen receptor modulator that alters estrogen receptor activity. Dr. O’Connor includes it among medications he does not recommend maintaining men on solely to attempt to reduce established fibrotic gynecomastia tissue.

Masteron

Masteron, or drostanolone, is an anabolic androgenic steroid discussed for its historical use in the treatment of metastatic breast cancer. Dr. O’Connor mentions this history while discussing estrogen, testosterone, anabolic steroids, and male breast health.

Condition Callouts

Gynecomastia

Gynecomastia is the development of glandular breast tissue in men and can become a firm, fibrotic mass once established. In men using testosterone or anabolic steroids, a breast mass should be properly evaluated rather than automatically treated by lowering estrogen or assuming androgen use is the only explanation.

Breast Cancer

Breast cancer can occur in men and must be considered when a new breast mass develops. Men using testosterone or anabolic steroids should not assume that every breast lump is gynecomastia, and a new or unexplained mass warrants appropriate medical evaluation.

Key Takeaways

A new breast mass in a man using testosterone should be properly evaluated before assuming it is gynecomastia.
True gynecomastia should be distinguished from excess chest fat and other causes of male breast enlargement.
Established gynecomastia can become a firm fibrotic glandular mass that may not respond meaningfully to estrogen-blocking medications.
Dr. O’Connor recommends consulting a plastic surgeon experienced specifically in gynecomastia when surgical removal is being considered.
Dr. O’Connor strongly cautions against chronically suppressing estrogen with aromatase inhibitors solely to treat an established gynecomastia mass.
The priority is identifying what a breast mass actually represents before choosing medication, surgery, or another treatment approach.